0001415889-23-011882.txt : 20230804 0001415889-23-011882.hdr.sgml : 20230804 20230804193310 ACCESSION NUMBER: 0001415889-23-011882 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230802 FILED AS OF DATE: 20230804 DATE AS OF CHANGE: 20230804 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Coen Stacy Ann CENTRAL INDEX KEY: 0001814150 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-17999 FILM NUMBER: 231145354 MAIL ADDRESS: STREET 1: 11 RUSH POND RD CITY: LAKEVILLE STATE: MA ZIP: 02347 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ImmunoGen, Inc. CENTRAL INDEX KEY: 0000855654 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 042726691 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 830 WINTER ST CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781)895-0600 MAIL ADDRESS: STREET 1: 830 WINTER ST CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: IMMUNOGEN INC DATE OF NAME CHANGE: 19920703 4 1 form4-08042023_110803.xml X0508 4 2023-08-02 0000855654 ImmunoGen, Inc. IMGN 0001814150 Coen Stacy Ann C/O IMMUNOGEN, INC. 830 WINTER STREET WALTHAM MA 02451 false true false false SVP & CHIEF BUSINESS OFFICER 0 Common Stock 2023-08-02 4 M 0 4255 4.92 A 15215 D Common Stock 2023-08-02 4 S 0 4255 18.12 D 10960 D Common Stock 2023-08-04 4 M 0 80326 4.92 A 91286 D Common Stock 2023-08-04 4 S 0 80326 17.05 D 10960 D Stock Option (Right to Buy) 4.92 2023-08-02 4 M 0 4255 0 D 2021-06-01 2030-06-01 Common Stock 4255 255745 D Stock Option (Right to Buy) 4.92 2023-08-04 4 M 0 80326 0 D 2021-06-01 2030-06-01 Common Stock 80326 175419 D The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.01 to $18.15, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.12, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges. Exercisable as to 25% on the first year anniversary of the grant and 6.25% quarterly for the subsequent three years. /s/ Renee Lentini, Attorney-in-Fact 2023-08-04